Nye og genopdagede medikamenter til behandling af tuberkulose

Christian Kraef; Troels Lillebæk; Åse Bengård Andersen; Ole Kirk

Nye og genopdagede medikamenter til behandling af tuberkulose

Translated title of the contribution: New and rediscovered treatments for tuberculosis

Christian Kraef, Troels Lillebæk, Åse Bengård Andersen, Ole Kirk

Research output: Contribution to journal › Journal article › Research › peer-review

14 Downloads (Pure)

Abstract

Tuberculosis (TB) is still a major challenge for global health, but in recent years there have been several important developments in treatment options. Shorter treatment regimens for latent TB, based on conventional drugs, offer better adherence and fewer side effects, while new and repurposed antibiotics have opened the door to more effective, shorter and less side effect-heavy treatments for drug susceptible TB and multidrug-resistant/extensively drug resistant TB as well as atypical mycobacterioses. This review investigates how these shorter and predominantly oral treatments, in the future, are expected to be used in combination with individualized precision medicine.

Translated title of the contribution	New and rediscovered treatments for tuberculosis
Original language	Danish
Article number	V10210783
Journal	Ugeskrift for Laeger
Volume	184
Issue number	10
Number of pages	6
ISSN	0041-5782
Publication status	Published - 2022

Access to Document

FulltextFinal published version, 179 KBLicence: CC BY-NC-ND

https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-03/v10210783_web.pdfLicence: CC BY-NC-ND

Cite this

@article{5752ba1010c34a0a918b7e1bd28fb61a,

title = "Nye og genopdagede medikamenter til behandling af tuberkulose",

abstract = "Tuberculosis (TB) is still a major challenge for global health, but in recent years there have been several important developments in treatment options. Shorter treatment regimens for latent TB, based on conventional drugs, offer better adherence and fewer side effects, while new and repurposed antibiotics have opened the door to more effective, shorter and less side effect-heavy treatments for drug susceptible TB and multidrug-resistant/extensively drug resistant TB as well as atypical mycobacterioses. This review investigates how these shorter and predominantly oral treatments, in the future, are expected to be used in combination with individualized precision medicine.",

author = "Christian Kraef and Troels Lilleb{\ae}k and Andersen, {{\AA}se Beng{\aa}rd} and Ole Kirk",

year = "2022",

language = "Dansk",

volume = "184",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "10",

}

TY - JOUR

T1 - Nye og genopdagede medikamenter til behandling af tuberkulose

AU - Kraef, Christian

AU - Lillebæk, Troels

AU - Andersen, Åse Bengård

AU - Kirk, Ole

PY - 2022

Y1 - 2022

N2 - Tuberculosis (TB) is still a major challenge for global health, but in recent years there have been several important developments in treatment options. Shorter treatment regimens for latent TB, based on conventional drugs, offer better adherence and fewer side effects, while new and repurposed antibiotics have opened the door to more effective, shorter and less side effect-heavy treatments for drug susceptible TB and multidrug-resistant/extensively drug resistant TB as well as atypical mycobacterioses. This review investigates how these shorter and predominantly oral treatments, in the future, are expected to be used in combination with individualized precision medicine.

AB - Tuberculosis (TB) is still a major challenge for global health, but in recent years there have been several important developments in treatment options. Shorter treatment regimens for latent TB, based on conventional drugs, offer better adherence and fewer side effects, while new and repurposed antibiotics have opened the door to more effective, shorter and less side effect-heavy treatments for drug susceptible TB and multidrug-resistant/extensively drug resistant TB as well as atypical mycobacterioses. This review investigates how these shorter and predominantly oral treatments, in the future, are expected to be used in combination with individualized precision medicine.

M3 - Tidsskriftartikel

C2 - 35315752

VL - 184

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 10

M1 - V10210783

ER -